You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ARCTURUS THERAPEUTICS HOLDINGS INC

Arcturus Therapeutics Holdings Inc XNAS: ARCT

Arcturus Therapeutics Holdings Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

13.27 0.39 (3.03%)

New 52W Low in past week

241.0K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Arcturus Therapeutics Hold... Key Metrics

Select

Market Capitalization

Below industry Median
359.9

PE TTM

Negative PE TTM
-4.4

Price to Book

Below industry Median
1.4

Institutional holding current Qtr %

High in industry
99.2

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-16.3

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-12.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-156.3

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-172.3

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-69.1

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-26.9
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
11.1 / 100
Valuation Score
Expensive Valuation
21.0 / 100
Momentum Score
Technically Bearish
25.9 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
73
1Yr Price target upside is 451%
10 analysts

4

S

18

W

2

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Arcturus Therapeutics Hold... Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260200400Actual RevenueAvg. Estimate
Miss

Arcturus Therapeutics Holdings Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-3
Avg. Estimate
-4.8
Low Estimate
-8.8
High Estimate
-2.4
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 61.3% in FY25

Consensus Recommendation

11 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.23Buy8Strong Buy

The consensus recommendation from 11 analysts for Arcturus Therapeutics Holdings Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Arcturus Therapeutics Hold... Stock Analysis

Arcturus Therapeutics Hold... stock analysis with key metrics, changes, and trends.

Arcturus Therapeutics Hold... MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$138.39 M12.27%negative

Annual Revenue fell 12.27%, in the last year to $138.39 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$80.94 M172.3%negative

Annual Net Profit fell 172.3% in the last year to $80.94 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio-4.45-negative

Price to Earning Ratio is -4.45, which is negative.

Stock Price$13.27-60.86%negative

Stock Price fell 60.86% and underperformed its sector by 70.76% in the past year.

Quarterly Revenue$21 M16.26%negative

Quarterly Revenue fell 16.26% YoY to $21 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$30 M156.3%negative

Quarterly Net profit fell 156.3% YoY to $30 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Mutual Fund Holding96.46 %-2.78%negative

Mutual Fund Holding decreased by 2.78% in the last quarter to 96.46.

Promoter Share Holding14.65 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 14.65%.

Institutional Holding99.23 %0.87%positive

Institutional Holding increased by 0.87% in the last quarter to 99.23.

VIEW LESS


Loading data..

Arcturus Therapeutics Holdings Inc - Company Profile

What does Arcturus Therapeutics Holdings Inc do?

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Arcturus Therapeutics Holdings Inc Management structure

All Gross Remunerations are in USD
Mr. Keith C. Kummerfeld
Senior Vice President, Finance, Corporate Controller and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Joseph Robert
Controller
-
2024
Gross Remuneration
Year
Mr. Andrew H. Sassine
Director, Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Joseph E. Payne
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Arcturus Therapeutics Holdings Inc Board of directors

All Gross Remunerations are in USD
Dr. Moncef M. Slaoui, PhD
Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. James F. Barlow
Independent Director
-
2024
Gross Remuneration
Year
Dr. Peter C. Farrell, A.M.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. Andrew H. Sassine
Director, Chief Financial Officer and Principal Ac
-
2024
Gross Remuneration
Year
Dr. Magda Marquet, PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. Joseph E. Payne
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Arcturus Therapeutics Holdings Inc FAQ

How is Arcturus Therapeutics Holdings Inc today?
Arcturus Therapeutics Holdings Inc today is trading in the green, and is up by 3.03% at 13.27.
Arcturus Therapeutics Holdings Inc is currently trading up 3.03% on an intraday basis. In the past week the stock fell -5.75%. stock has been down -19.62% in the past quarter and fell -60.86% in the past year. You can view this in the overview section.